HepaCAM inhibits clear cell renal carcinoma 786-0 cell proliferation via blocking PKCε translocation from cytoplasm to plasma membrane

[1]  Qiuju Wang,et al.  hepaCAM and p-mTOR closely correlate in bladder transitional cell carcinoma and hepaCAM expression inhibits proliferation via an AMPK/mTOR dependent pathway in human bladder cancer cells. , 2013, The Journal of urology.

[2]  C. Denkert,et al.  Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer , 2013, Journal of Cancer Research and Clinical Oncology.

[3]  Xiao-hou Wu,et al.  Exploration of the correlations between interferon-γ in patient serum and HEPACAM in bladder transitional cell carcinoma, and the interferon-γ mechanism inhibiting BIU-87 proliferation. , 2012, The Journal of urology.

[4]  J. Blando,et al.  Activation of Nuclear Factor κB (NF-κB) in Prostate Cancer Is Mediated by Protein Kinase C ϵ (PKCϵ)* , 2012, The Journal of Biological Chemistry.

[5]  Qiao Zhang,et al.  HepaCAM induces G1 phase arrest and promotes c‐Myc degradation in human renal cell carcinoma , 2011, Journal of cellular biochemistry.

[6]  W. Zhong,et al.  Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. , 2011, Cancer research.

[7]  E. Ignatowicz,et al.  Protein kinase C as a cancer marker and target for anticancer therapy , 2011 .

[8]  Lorenzo Marconi,et al.  EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.

[9]  Jean-Jacques Patard,et al.  EAU guidelines on renal cell carcinoma: the 2010 update. , 2010, European urology.

[10]  Xiao-hou Wu,et al.  Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma , 2010, World Journal of Urology.

[11]  Ling Yan,et al.  Expression of hepaCAM and its effect on proliferation of tumor cells in renal cell carcinoma. , 2010, Urology.

[12]  Jie Lin,et al.  Functional significance of the hepaCAM gene in bladder cancer , 2010, BMC Cancer.

[13]  D. Alkon,et al.  Reduction of β-Amyloid Levels by Novel Protein Kinase Cϵ Activators , 2009, The Journal of Biological Chemistry.

[14]  Ting Zhang,et al.  The immunoglobulin‐like cell adhesion molecule hepaCAM induces differentiation of human glioblastoma U373‐MG cells , 2009, Journal of cellular biochemistry.

[15]  G. Labesse,et al.  A 20-Amino Acid Module of Protein Kinase Cϵ Involved in Translocation and Selective Targeting at Cell-Cell Contacts* , 2009, The Journal of Biological Chemistry.

[16]  Ting Zhang,et al.  Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells. , 2008, Carcinogenesis.

[17]  G. Steinberg,et al.  ɛPKC confers acute tolerance to cerebral ischemic reperfusion injury , 2008, Neuroscience Letters.

[18]  G. Wilding,et al.  Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. , 2007, Cancer research.

[19]  A. Basu,et al.  Protein kinase Cε makes the life and death decision , 2007 .

[20]  Lei Xiao,et al.  Protein kinase C epsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner. , 2007, Cancer research.

[21]  D. Mochly‐Rosen,et al.  Rational design of a selective antagonist of epsilon protein kinase C derived from the selective allosteric agonist, pseudo-RACK peptide. , 2007, Journal of molecular and cellular cardiology.

[22]  J. Cawley,et al.  Central role of protein kinase Cepsilon in constitutive activation of ERK1/2 and Rac1 in the malignant cells of hairy cell leukemia. , 2007, The American journal of pathology.

[23]  N. Haseke,et al.  Modern Therapeutic Approaches in Metastatic Renal Cell Carcinoma , 2007 .

[24]  M. C. Moh,et al.  Structural and Functional Analyses of a Novel Ig-like Cell Adhesion Molecule, hepaCAM, in the Human Breast Carcinoma MCF7 Cells* , 2005, Journal of Biological Chemistry.

[25]  Shali Shen,et al.  Cloning and characterization of hepaCAM, a novel Ig-like cell adhesion molecule suppressed in human hepatocellular carcinoma. , 2005, Journal of hepatology.

[26]  B. Seliger,et al.  Regulation of beta1 integrin expression by PKCepsilon in renal cancer cells. , 2004, International journal of oncology.

[27]  Y. Akita.  Protein Kinase C-ε (PKC-ε): Its Unique Structure and Function , 2002 .

[28]  K. Kashiwagi,et al.  Importance of C1B Domain for Lipid Messenger-induced Targeting of Protein Kinase C* , 2002, The Journal of Biological Chemistry.

[29]  M. Rumsby,et al.  Changes in protein kinase C epsilon phosphorylation status and intracellular localization as 3T3 and 3T6 fibroblasts grow to confluency and quiescence: a role for phosphorylation at ser-729? , 2000, The Biochemical journal.

[30]  D. Mochly‐Rosen,et al.  The Coatomer Protein β′-COP, a Selective Binding Protein (RACK) for Protein Kinase Cε* , 1997, The Journal of Biological Chemistry.

[31]  F. Greene,et al.  AJCC cancer staging handbook : from the AJCC cancer staging manual , 2002 .

[32]  J. Eble,et al.  CLASSIFICATION OF RENAL CELL CARCINOMA: WORK GROUP , 1997 .